A polymorphism of G-protein coupled receptor kinase5 alters agonist-promoted desensitization of beta2-adrenergic receptors.

Beta-agonist treatment of asthma displays substantial interindividual variation, which has prompted polymorphism discovery and characterization of beta2-adrenergic (beta2AR) signaling genes. beta2AR function undergoes desensitization during persistent agonist exposure because of receptor phosphorylation by G-protein coupled receptor kinases (GRKs). GRK5 was found to be highly expressed in airway smooth muscle, the tissue target for beta-agonists. The coding region is polymorphic at codon 41, where Gln can be substituted by Leu (minor allele), but almost exclusively in those of African descent. In transfected cells, GRK5-Leu41 evoked a greater degree of agonist-promoted desensitization of adenylyl cyclase compared with GRK5-Gln41. Consistent with this functional effect, agonist-promoted beta2AR phosphorylation was greater in cells expressing GRK5-Leu41, as was the rate of agonist-promoted receptor internalization. In studies with mutated beta2AR lacking PKA-phosphorylation sites, this phenotype was confirmed as being GRK-specific. So, GRK5-Leu41 represents a gain-of-function polymorphism that evokes enhanced loss-of-function of beta2AR during persistent agonist exposure, and thus may contribute to beta-agonist variability in asthma treatment of African-Americans.

[1]  J. Spertus,et al.  A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure , 2008, Nature Medicine.

[2]  Rasmus Jorgensen,et al.  Phosphorylation of the beta2-adrenergic receptor in plasma membranes by intrinsic GRK5. , 2007, Biochemistry.

[3]  Robert J. Lefkowitz,et al.  G-protein-coupled Receptor Kinase Specificity for β-Arrestin Recruitment to the β2-Adrenergic Receptor Revealed by Fluorescence Resonance Energy Transfer* , 2006, Journal of Biological Chemistry.

[4]  S. Liggett,et al.  α2A- and α2C-Adrenergic Receptors Form Homo- and Heterodimers: The Heterodimeric State Impairs Agonist-Promoted GRK Phosphorylation and β-Arrestin Recruitment† , 2006 .

[5]  S. Weiss,et al.  Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. , 2005, Human molecular genetics.

[6]  E. Israel,et al.  Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial , 2004, The Lancet.

[7]  B. J. Knoll,et al.  Endosome sorting of β2‐adrenoceptors is GRK5 independent , 2004 .

[8]  S. Liggett,et al.  An Ile to Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced beta2-adrenergic receptor stimulation. , 2003, Pharmacogenetics.

[9]  S. Liggett,et al.  Hierarchy of Polymorphic Variation and Desensitization Permutations Relative to β1- and β2-Adrenergic Receptor Signaling* , 2003, The Journal of Biological Chemistry.

[10]  B. Lipworth.  Airway Subsensitivity with Long-Acting β2-Agonists , 1997 .

[11]  J. Freedman,et al.  Structure and Expression of Novel Spliced Leader RNA Genes in Caenorhabditis elegans(*) , 1995, The Journal of Biological Chemistry.

[12]  M. Caron,et al.  Phosphorylation and Desensitization of the Human -Adrenergic Receptor , 1995, The Journal of Biological Chemistry.

[13]  M. Caron,et al.  Phosphorylation and desensitization of the human beta 1-adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase. , 1995, The Journal of biological chemistry.

[14]  I. Hall,et al.  Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. , 1995, American journal of respiratory cell and molecular biology.

[15]  S. Green,et al.  A proline-rich region of the third intracellular loop imparts phenotypic beta 1-versus beta 2-adrenergic receptor coupling and sequestration. , 1994, The Journal of biological chemistry.

[16]  S. Green,et al.  Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. , 1994, Biochemistry.

[17]  S. Liggett.  Desensitization of the beta-adrenergic receptor: distinct molecular determinants of phosphorylation by specific kinases. , 1991, Pharmacological research.

[18]  P. Dorinsky,et al.  The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. , 2006, Chest.

[19]  R. Lefkowitz,et al.  G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by fluorescence resonance energy transfer. , 2006, The Journal of biological chemistry.

[20]  D. Vaughan,et al.  Endosome sorting of beta 2-adrenoceptors is GRK5 independent. , 2004, British journal of pharmacology.

[21]  E. Silverman,et al.  Heterogeneity of therapeutic responses in asthma. , 2000, British medical bulletin.

[22]  B. Lipworth.  Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern? , 1997, Drug safety.